All the news Showing 10 of 553 articlesGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Pan-genotypic regimens New pangenotypic hepatitis C drug combinations recommended for approval in the European Union Keith Alcorn / 26 June 2017 Two new pangenotypic direct-acting antiviral combinations have received positive opinions from the scientific committee of the European Medicines Agency (the CHMP) and should receive European Union marketing approval in next ... Treatment outcomes Experts question Cochrane review of hepatitis C treatment Keith Alcorn / 15 June 2017 A systematic review of hepatitis C direct-acting antiviral (DAA) studies published by the Cochrane Collaboration has been strongly criticised by doctors and advocates for its conclusion that there is no ... Screening policy Six-question risk score can identify HIV-positive gay men needing testing for acute hepatitis C Roger Pebody / 13 June 2017 Six questions can identify HIV-positive gay men who are at elevated risk of having acute (recent) hepatitis C infection and who would benefit from further testing, according to a paper ... Interferon-free regimens Sofosbuvir plus ribavirin cures teens with genotype 2 or 3 hepatitis C Liz Highleyman / 05 June 2017 A two-drug regimen of sofosbuvir (Sovaldi) and ribavirin taken for 12 weeks led to sustained virological response in all treated adolescents with hepatitis C virus (HCV) genotype 2, while a 24-week course ... Interferon-free regimens Indonesian buyers club helps people obtain generic hepatitis C treatment Liz Highleyman / 30 May 2017 A community-led buyers club in Indonesia has helped more than 100 people get generic direct-acting antiviral (DAA) drugs to treat hepatitis C and is seeing a high cure rate, according to a ... Treatment for people who use drugs Hepatitis C virus reinfection is uncommon after being cured with DAAs Liz Highleyman / 22 May 2017 Most people on opiate substitution therapy were successfully treated for hepatitis C with an interferon-free regimen of grazoprevir/elbasvir (Zepatier), and only a small number became reinfected during three years of follow-up, researchers reported ... Epidemiology New hepatitis C infections tripled in US over the past five years Liz Highleyman / 22 May 2017 The US Centers for Disease Control and Prevention (CDC) released new data last week showing that the number of new hepatitis C virus (HCV) infections reported to the agency nearly tripled between 2010 ... HBV vaccination Children on immunosuppressive therapy may lose hepatitis B vaccine protection Liz Highleyman / 22 May 2017 More than half of children treated with immunosuppressive drugs for gastrointestinal or rheumatological conditions no longer had protective levels of antibodies against hepatitis B virus (HBV) and may require repeat vaccination, according to ... Harm reduction interventions and policy Few young people with HCV in the US live close to needle-exchange services Michael Carter / 11 May 2017 The vast majority (80%) of young people with hepatitis C virus (HCV) infection in the United States have to travel at least ten miles to access needle exchange programmes, investigators report in the ... Treatment in cirrhosis Albumin reduces complications and improves survival in people with decompensated cirrhosis Liz Highleyman / 08 May 2017 Long-term administration of human albumin was associated with fewer serious complications, less hospitalisation, better quality of life and longer survival for people with decompensated liver cirrhosis, according to a report at the International ... ← First12345...56Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Noticeboard Email bulletins News feeds